Topiramate: A new antiepileptic drug for refractory epilepsy

Seizure

Volumn 5, Issue 3, 1996, Pages 199-203

  Walker, M C ^a   Sander, J W A S ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NONE

Author keywords

New antiepileptic drug; Refractory epilepsy; Topiramate

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ANTICONVULSIVE AGENT; GLUTAMATE RECEPTOR; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; SODIUM CHANNEL; TOPIRAMATE;

ATAXIA; CLINICAL TRIAL; CONCENTRATION LOSS; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; EPILEPSY; FATIGUE; FOCAL EPILEPSY; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; NEPHROLITHIASIS; ORAL DRUG ADMINISTRATION; PARESTHESIA; PRIORITY JOURNAL; SEIZURE; SHORT SURVEY; SOMNOLENCE; VERTIGO; WEIGHT REDUCTION;

EID: 0029857877     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1059-1311(96)80036-7     Document Type: Article

References (33)

1. Walker, M.C. and Sander, J.W.A.S. Overtreatment with antiepileptic drugs: how extensive is the problem? CNS Drugs 1994; 2: 335-340.
2. Walker, M.C. and Sander, J.W.A.S. The impact of new antiepileptic drugs on the prognosis of epilepsy: seizure freedom should be the ultimate goal. Neurology 1996; 46: 912-914.
3. Shank, R.P., Gardocki, J.F., Vaught, J.L. et al. Topiramate: preclinical evaluation of a structurally novel anticonvulsant. Epilepsia 1994; 35: 450-460.
4. Coulter, D.A., Sombati, S. and DeLorenzo, R.J. Selective effects of topiramate on sustained repetitive firing and spontaneous bursting in cultured hippocampal neurons. Epilepsia 1993; 34 (Suppl 2): S123.
5. Brown, S.D., Wolf, H.H., Swinyard, E.A., Twyman, R.E. and White, H.S. The novel anticonvulsant topiramate enhances GABA-mediated chloride flux. Epilepsia 1993; 34 (Suppl. 2): 5122-5123.
6. Topamax product monograph. Cheshire, Gardiner-Caldwell Communications Ltd, 1995.
7. Easterling, D.E., Zakszewski, T., Moyer, M.D., Margul, B.L., Marriott, T.B. and Nayak, R.K. Multiple dose pharmacokinetics of topiramate in healthy male subjects. Epilepsia 1988; 29: 662.
8. Doose, D.R., Gisclon, L.G., Stellar, S.M., Riffits, J.M. and Hills, J.F. The effect of food on the bioavailability of topiramate from 100-400 mg tablets in healthy male subjects. Epilepsia 1992; 33 (Suppl. 3): S105.
9. Floren, K.L., Graves, N.M., Leppik, I.E., Remmel, R.P., Margul, B. and Doose, D.R. Pharmacokinetics of topiramate in patients with partial epilepsy receiving phenytoin or valproic acid. Epilepsia 1989; 30: 646.
10. Doose, D., Walker, S.A., Sachdeo, R., Kramer, L.D. and Nayak, R.K. Steady-state pharmacokinetics of tegretol (carbamazepine) and topamax (topiramate) in patients with epilepsy on monotherapy, and during combination therapy. Epilepsia 1994; 35 (Suppl. 8): 554.
11. Wilensky, A.J., Ojermann, L.M., Chmelir, T., Margul, B.L. and Doose, D.R. Topiramate pharmacokinetics in epileptic patients receiving carbamazepine. Epilepsia 1989; 30: 645.
12. Gisclon, L.G., Curtin, C.R. and Kramer, L.D. The steady-state pharmacokinetics of phenytoin (dilantin) and topiramate (topamax) in epileptic patients on monotherapy and during combination therapy. Epilepsia 1994; 35 (Suppl. 8): 554.
13. Levy, R.H., Bishop, F., Streeter, A.J. et al. Explanation and prediction of drug interactions with topiramate using a CYP450 inhibition spectrum. Epilepsia 1995; 36 (Suppl. 4): 547.
14. Liao, S., Rosenfeld, W.E., Palmer, M. et al. Steady-state pharmacokinetics of topiramate and valproic acid in patients with epilepsy on monotherapy and during combination therapy. Epilepsia 1994; 35 (Suppl. 8): 5117.
15. Bourgeois, B.F. Drug interaction profile of topiramate. Clinical courier 1995; 13: 4-5.
16. Reife, R.A., Pledger, G., Doose, D., Lim, P. and Ward, C. Topiramate PK/PD analyses. Epilepsia 195; 36 (Suppl. 3): S152.
17. Walker, M.C. and Patsalos, P.N. Clinical pharmacokinetics of new antiepileptic drugs. Pharmacology and Therapeutics 1995; 67: 351-384.
18. Sharief, M.W., Sander, J.W.A.S., Patsalos, P.N. and Shorvon, S.D. Double blind parallel comparison of topiramate with placebo in patients with refractory partial epilepsy. Seizure 1992; 1 (Suppl. A): P7/45.
19. Sharief, M.W., Sander, J.W.A.S. and Shorvon, S.D. Long-term treatment with topiramate in refractory partial epilepsy: two-year follow-up study. Seizure 1992; 1 (Suppl. A): P7/47.
20. Mikkelsen, M., Dam, M. and Ostergaard, L. Topiramate as add-on therapy in refractory partial seizures. Seizure 1992; 1 (Suppl. A): P7/31.
21. Engelskjon, T., Johannessen, S.I., Kloster, R. et al. Topiramate in the treatment of refractory partial epilepsy - an efficacy and tolerance study. Seizure 1992; 1 (Suppl. A): p7/K.
22. Espe-Lillo, J., Ritter, F.J., Frost, M.D., Spiegel, R.H. and Reife, R. Safety and efficacy of topiramate in pediatric subjects. Epilepsia 1994; 35 (Suppl. 8): S162.
23. French, J. New AED options: clinical efficacy - the US experience. Clinical courier 1995; 13: 7-8.
24. Pledger, G., Reife, R.A., Lim, P. and Karim, R. Overview of topiramate efficacy from adjunctive therapy trials. Epilepsia 1995; 36 (Suppl. 3): S150.
25. Martinez-Lage, J., Ben-Menachem, E., Shorvon, S.D. and Weber, M. Double-blind, placebo-controlled trial of 400 mg/day topiramate as add-on therapy in patients with refractory partial epilepsy. Epilepsia 1995; 36 (Suppl. 3): S149.
26. Tassinari, C., Chauvel, P., Chodkiewicz, J. et al. Double-blind, placebo-controlled trial of 600 mg/day topiramate as add-on therapy in patients with refractory partial epilepsy. Epilepsia 1995; 35 (Suppl. 3): S150.
27. Ben-Menachem, E., Dam, M., Henrikson, O. and Schmidt, D. Double-blind, placebo-controlled trial of 800 mg/day topiramate as add-on therapy in patients with refractory partial epilepsy. Epilepsia 1995; 36 (Suppl. 3): S150.
28. Sachdeo, S.K., Sachdeo, R.C., Reife, R.A., Lim, P. and Pledger, G. Topiramate; double-blind trial as monotherapy. Epilepsia 1995; 36 (Suppl. 4): S33.
29. Wasserstein, A.G., Rak, I. and Reife, R.A. Nephrolithiasis during treatment with topiramate. Epilepsia 1995; 36 (Suppl. 3): S153.
30. Wasserstein, A.G., Rak, I. and Reife, R.A. Investigation of the mechanistic basis for topiramate-associated nephrolithiasis: examination of urinary and serum constituents. Epilepsia 1995; 36 (Suppl. 3): S153.
31. Walker, M.C. and Patsalos, P.N. The safety and tolerability of gabapentin. Reviews of Contemporary Pharmacotherapy 1996; (in press).
32. Ben-Menachem, E. and Abrahamsson, H. Gastroscopic evaluation of patients with complex partial seizures treated with topiramate. Epilepsia 1994; 35 (Suppl. 8): S116.
33. Thanedar, S., Rosenfeld, W.E. and Doose, D. Topiramate well tolerated by pediatric patients. Epilepsia 1995; 36 (Suppl. 4): S34.